Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Med Tr Prom Ekol ; (7): 37-42, 2011.
Article in Russian | MEDLINE | ID: mdl-22043523

ABSTRACT

The threat of industrial chemical accidents and terrorist attacks requires the development of safety regulations for the cleanup of contaminated surfaces. This paper presents principles and a methodology for the development of a new toxicological parameter, "relative value unit" (RVU) as the primary decontamination standard.


Subject(s)
Chemical Hazard Release , Decontamination , Government Regulation , Occupational Health/legislation & jurisprudence , Terrorism , Chemical Hazard Release/legislation & jurisprudence , Decontamination/legislation & jurisprudence , Decontamination/methods , Environmental Exposure/adverse effects , Environmental Exposure/analysis , Humans , Models, Theoretical , No-Observed-Adverse-Effect Level , Terrorism/legislation & jurisprudence , Xenobiotics/toxicity
2.
Probl Tuberk Bolezn Legk ; (9): 30-3, 2007.
Article in Russian | MEDLINE | ID: mdl-18038603

ABSTRACT

The authors used their immunological correction method to treat 154 patients with progressive pulmonary tuberculosis. Of them, 38 patients received standard antituberculosis therapy (Group 1), 39 had additionally paravasal lymphotrophic immunological correction (Group 2), and 38 took antituberculous drugs in accordance with individual regimens (Group 3), and 39 patients were treated by individual regimens during immunological correction (Group 4). After termination of the basic course of chemotherapy, clinical cure was achieved in 61.1, 76.3, 72.2, and 94.7%, respectively (p < 0.05). During the basic course, mortality was 11.1, 5.3, and 5.5% in the first three groups. By taking into account the immunological status of patients with caseous pneumonia, disseminated, and multicavernous pulmonary tuberculous lesion, immunological correction is indicated early in the basic course of therapy.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Antitubercular Agents/therapeutic use , Immunity, Cellular/immunology , Tuberculosis, Pulmonary/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Drug Therapy, Combination , Follow-Up Studies , Humans , Immunity, Cellular/drug effects , Infant , Middle Aged , Oligopeptides/therapeutic use , T-Lymphocytes/immunology , Thymus Hormones/therapeutic use , Time Factors , Treatment Outcome , Tuberculosis, Pulmonary/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...